Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma
Journal of Neuropathology & Experimental Neurology · 2024
DOI: 10.1093/jnen/nlae076 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Neuropathology & Experimental Neurology, 2024. Verfasst von M Adelita Vizcaino und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase Inhibitor p16, Astrocytoma, Brain Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mayo Clinic Department of Laboratory Medicine and Pathology, Mayo Clinic institutional, Mayo Clinic institutional funding.
Abstract (Originalsprache)
Pleomorphic xanthoastrocytomas (PXAs) harbor CDKN2A homozygous deletion in >90% of cases, resulting in loss of p16 expression by immunohistochemistry. Considering the proximity of MTAP to CDKN2A and their frequent concurrent deletions, loss of MTAP expression may be a surrogate for CDKN2A homozygous deletion. We evaluated p16 and MTAP expression in 38 patient PXAs (CNS WHO grade 2: n = 23, 60.5%; grade 3: n = 15, 39.5%) with available chromosomal microarray data to determine whether MTAP can be utilized independently or in combination with p16 to predict CDKN2A status. CDKN2A, CDKN2B, and MTAP homozygous deletion were present in 37 (97.4%), 36 (94.7%), and 25 (65.8%) cases, respectively. Expression of p16 was lost in 35 (92.1%) cases, equivocal in one (2.6%), and failed in 2 (5.3%), while MTAP expression was lost in 27 (71.1%) cases, retained in 10 (26.3%), and equivocal in one (2.6%). This yielded a sensitivity of 94.6% for p16 and 73.0% for MTAP in detecting CDKN2A homozygous deletion through immunohistochemistry. MTAP expression was lost in the 2 cases with failed p16 staining (combined sensitivity of 100%). Our findings demonstrate that combined p16 and MTAP immunostains correctly detect CDKN2A homozygous deletion in PXA, while MTAP expression alone shows reduced sensitivity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory of Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
- Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
- Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, United States.
ORCID-Profile: M Adelita Vizcaino
Förderung
- Mayo Clinic Department of Laboratory Medicine and Pathology
- Mayo Clinic institutional
- Mayo Clinic institutional funding
- NCI NIH HHS
Zitieren
APA
Vizcaino, M. A., Giannini, C., Vaubel, R. A., Nguyen, A. T., Trejo-Lopez, J. A., Raghunathan, A., Jenkins, S. M., Jenkins, R. B., & Zepeda Mendoza, C. J. (2024). Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma. Journal of Neuropathology & Experimental Neurology. https://doi.org/10.1093/jnen/nlae076
Vancouver
Vizcaino MA, Giannini C, Vaubel RA, Nguyen AT, Trejo-Lopez JA, Raghunathan A, et al. Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma. Journal of Neuropathology & Experimental Neurology. 2024. doi:10.1093/jnen/nlae076
BibTeX
@article{Vizcaino2024,
author = {Vizcaino, M Adelita and Giannini, Caterina and Vaubel, Rachael A and Nguyen, Aivi T and Trejo-Lopez, Jorge A and Raghunathan, Aditya and Jenkins, Sarah M and Jenkins, Robert B and Zepeda Mendoza, Cinthya J},
title = {Comparing loss of p16 and MTAP expression in detecting CDKN2A homozygous deletion in pleomorphic xanthoastrocytoma},
journal = {Journal of Neuropathology & Experimental Neurology},
year = {2024},
doi = {10.1093/jnen/nlae076}
}
EUVIMED